Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy

Journal of Clinical Oncology

Volumn 26, Issue 16, 2008, Pages 2745-2753

  Yang, Chih Hsin ^a   Yu, Chong Jen ^a   Shih, Jin Yuan ^a   Chang, Yeun Chung ^a   Hu, Fu Chang ^a   Tsai, Meng Chin ^a   Chen, Kuan Yu ^a   Lin, Zhong Zhe ^a   Huang, Ching Ju ^a   Shun, Chia Tung ^a   Huang, Chin Lun ^a   Bean, James ^a   Cheng, Ann Lii ^a   Pao, William ^a   Yang, Pan Chyr ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; K RAS PROTEIN; PLATINUM DERIVATIVE; SCATTER FACTOR RECEPTOR; STEROID; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EXON; FEMALE; FOLLOW UP; GENE DELETION; GENE MUTATION; GENE SEQUENCE; HUMAN; INTERSTITIAL LUNG DISEASE; LIVER TOXICITY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIVARIATE ANALYSIS; NAUSEA; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SEX DIFFERENCE; SKIN TOXICITY; TREATMENT RESPONSE; VOMITING; DRUG EFFECT; GENETICS; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY; MUTATION; ONCOGENE RAS; PATHOLOGY; PREDICTION AND FORECASTING; PROTO ONCOGENE; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE DELETION; GENES, ERBB-1; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; QUINAZOLINES; SURVIVAL ANALYSIS;

EID: 45749120442     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.6695     Document Type: Article

References (42)

1. Shepherd FA, Rodrigues Pereira J, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
2. Chang A, Parikh P, Thongprasert S, et al: Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study. J Thorac Oncol 1:847-855, 2006
3. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21:2237-2246, 2003
4. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005
5. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
6. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
7. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., et al: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24:5034-5042, 2006
8. Tsao MS, Sakurada A, Cutz JC, et al: Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N Engl J Med 353:133-144, 2005
9. Yang CH, Shih JY, Chen KC, et al: Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer. Cancer 107:1873-1882, 2006
10. Lee DH, Han JY, Lee HG, et al: Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 11:3032-3037, 2005
11. Lange T, Muller-Tidow C, Serve H, et al: First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer. Oncol Rep 14:1539-1542, 2005
12. Asahina H, Yamazaki K, Kinoshita I, et al: A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 95:998-1004, 2006
13. Niho S, Kubota K, Goto K, et al: First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 24:64-69, 2006
14. Suzuki R, Hasegawa Y, Baba K, et al: A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer. Br J Cancer 94:1599-1603, 2006
15. Kimura H, Kasahara K, Shibata K, et al: EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer. J Thorac Oncol 1:260-267, 2006
16. Lin WC, Chiu CH, Liou JL, et al: Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. Lung Cancer 54:193-199, 2006
17. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004
18. Han SW, Kim TY, Hwang PG, et al: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23:2493-2501, 2005
19. Jänne PA, Engelman JA, Johnson BE: Epidermal growth factor receptor mutations in non-small-cell lung cancer: Implications for treatment and tumor biology. J Clin Oncol 23:3227-3234, 2005
20. Mitsudomi T, Kosaka T, Endoh H, et al: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23:2513-2520, 2005
21. Shih JY, Gow CH, Yu CJ, et al: Epidermal growth factor receptor mutations in needle biopsy/ aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 118:963-969, 2006
22. Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73, 2005
23. Inukai M, Toyooka S, Ito S, et al: Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 66:7854-7858, 2006
24. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043, 2007
25. Bean J, Brennan C, Shih JY, et al: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104:20932-20937, 2007
26. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
27. Pao W, Wang TY, Riely GJ, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17, 2005
28. Yang CH, Yu CJ, Chen KY, et al: A phase II study of gefitinib as first line treatment for good performance advanced or metastatic non-small-cell lung cancer in East Asian patients. J Clin Oncol 24:405s, 2006 (suppl; abstr 7167)
29. Liu F, Jiang B, Gong SJ, et al: Mutational analysis of EGFR and K-RAS in Chinese patients with non-small cell lung cancer. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 24:31-34, 2007
30. Yoshida K, Yatabe Y, Park JY, et al: Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol 2:22-28, 2007
31. Sunaga N, Tomizawa Y, Yanagitani N, et al: Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 56:383-389, 2007
32. Inoue A, Suzuki T, Fukuhara T, et al: Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24:3340-3346, 2006
33. Sutani A, Nagai Y, Udagawa K, et al: Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 95:1483-1489, 2006
34. Sequist LV: ITARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor-mutated non-small-cell lung cancer tumors. J Clin Oncol 25:386s, 2007 (suppl; abstr 7504)
35. Cheng TL, Chang MY, Huang SY, et al: Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer. Chest 128:1453-1460, 2005
36. Qiao H, Hung W, Tremblay E, et al: Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival. J Cell Biochem 86:665-677, 2002
37. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655, 2005
38. Sone T, Kasahara K, Kimura H, et al: Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer. Cancer 109:1836-1844, 2007
39. Bell DW, Lynch TJ, Haserlat SM, et al: Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23:8081-8092, 2005
40. Eberhard DA, Johnson BE, Amler LC, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900-5909, 2005
41. Sasaki H, Endo K, Takada M, et al: EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer 58:324-328, 2007
42. Kimura H, Kasahara K, Kawaishi M, et al: Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 12:3915-3921, 2006